Apellis Pharmaceuticals Return On Equity History
| APLS Stock | USD 17.25 -0.39 -2.21% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter 0.06048408 | Current Value 0.0635 | Quarterly Volatility 2.16799339 |
Macro event markers
Apellis Pharmaceuticals's Return On Equity is influenced by both company-specific factors and broader sector dynamics.
Latest Apellis Pharmaceuticals' Return On Equity Growth Pattern
The Return On Equity line for Apellis Pharmaceuticals covering 13 reporting periods is displayed in the chart. The multi-year path has been stable, with the moving downward direction shaping expectations. The interplay between trend direction and volatility shapes the risk profile of this metric. The annual reporting cadence smooths out intra-year noise, revealing the underlying direction. Flat stretches in Apellis Pharmaceuticals' Return On Equity may reflect operational stability or a pause between growth phases.
| View | Last Reported 0.0748 | 10 Years Trend |
|
Return On Equity |
| Timeline |
Return On Equity Trend Statistics
| Arithmetic Mean | -1.74 | |
| Coefficient Of Variation | -124.65 | |
| Mean Deviation | 1.44 | |
| Median | -0.88 | |
| Standard Deviation | 2.17 | |
| Sample Variance | 4.70 | |
| Range | 8.9653 | |
| R-Value | -0.14 | |
| Mean Square Error | 4.92 | |
| R-Squared | 0.02 | |
| Significance | 0.60 | |
| Slope | -0.06 | |
| Total Sum of Squares | 75.20 |
Apellis Pharmaceuticals Return On Equity History
| 2026 | 0.0635 | ||
| 2025 | 0.0605 | ||
| 2024 | -0.87 | ||
| 2023 | -2.72 | ||
| 2022 | -3.84 | ||
| 2021 | -3.76 | ||
| 2020 | -1.69 | ||
| 2019 | -8.9 | ||
| 2018 | -0.79 | ||
| 2017 | -0.34 | ||
| 2016 | -1.14 | ||
| 2015 | -1.33 | ||
| 2014 | -0.82 |
Related Accounts
| Last Reported | End Of Year Estimate | ||
| Return On Tangible Assets | 0.02 | 0.02 | |
| Return On Capital Employed | 0.07 | 0.08 | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.06 | 0.06 |
Methodology, Assumptions & Data Sources
The chart shows how Apellis Pharmaceuticals's Return On Equity has moved over time. Apellis Pharmaceuticals has a current Return On Equity of 0.0748. Return on Equity (ROE) measures how effectively a company converts shareholders' equity into net income. It is calculated by dividing net income by average shareholders' equity, and it reflects management's ability to generate profit from the capital investors have committed. ROE is one of the most widely used profitability ratios because it ties directly to shareholder value creation. A strong fit to a straight line suggests the trend is dependable.
Apellis Pharmaceuticals metrics are compiled from periodic company reporting and market reference feeds and normalized before display. Sell-side coverage, where present, supplements the data shown. Not all fields update in real time. This section presents reference data and historical patterns only and does not constitute an investment recommendation or advice.